OPKO shares slipped 1.1% after earnings, a roughly flat reaction. The call highlighted pipeline progress and the planned LabCorp exit, but provided no financial outlook figures in the transcript excerpt, leaving the near-term performance picture unclear.
- OPKO said the LabCorp transaction, once closed, will complete its exit from clinical laboratory services and refocus the company on biotech and global products.
- ModeX’s MDX-2001 Phase I study had enrolled 41 patients as of September 30; subcutaneous dosing is expected to begin in late 2026 or early 2027.
- MDX-2003 continued dose escalation, with six sites active as of September 30 and two more being added; eight European sites are planned by early 2027.
- MDX-2004 had enrolled 16 patients and advanced to its fourth dose cohort; subcutaneous studies are expected to begin in early 2027.
- OPKO repurchased over 7 million shares during the quarter, with more than $80 million remaining under its $220 million authorization.
Community Discussion